Yabao Pharmaceutical Group Co., Ltd (SHA:600351)
China
· Delayed Price · Currency is CNY 7.08
+0.16 (2.31%)
Apr 30, 2026, 3:00 PM CST
SHA:600351 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 2,198 | 2,240 | 2,652 | 2,880 | 2,681 | 2,681 | Upgrade
|
| Other Revenue | - | - | 34.52 | 29.46 | 37.45 | 83.2 | Upgrade
|
| Revenue | 2,198 | 2,240 | 2,686 | 2,910 | 2,718 | 2,764 | Upgrade
|
| Revenue Growth (YoY) | -13.12% | -16.60% | -7.69% | 7.05% | -1.66% | 6.21% | Upgrade
|
| Cost of Revenue | 1,042 | 1,064 | 1,323 | 1,246 | 1,216 | 1,095 | Upgrade
|
| Gross Profit | 1,156 | 1,176 | 1,363 | 1,664 | 1,502 | 1,669 | Upgrade
|
| Selling, General & Admin | 679.25 | 697.86 | 913.51 | 1,228 | 1,159 | 1,296 | Upgrade
|
| Research & Development | 114.05 | 117.27 | 139.52 | 118.29 | 130.62 | 157.13 | Upgrade
|
| Other Operating Expenses | 9.96 | 11.43 | 31.39 | 31.34 | 33.98 | 33.38 | Upgrade
|
| Operating Expenses | 803.27 | 826.56 | 1,086 | 1,373 | 1,324 | 1,473 | Upgrade
|
| Operating Income | 352.3 | 349.71 | 276.84 | 291.5 | 178.07 | 196.65 | Upgrade
|
| Interest Expense | - | - | -5.35 | -12.3 | -18.77 | -22.61 | Upgrade
|
| Interest & Investment Income | 74.34 | 74.04 | 6.45 | 9.49 | 8.18 | 22.04 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | 0.05 | -0.03 | 0.27 | -0.13 | Upgrade
|
| Other Non Operating Income (Expenses) | 18.73 | 15.1 | 5.96 | -9.75 | -8.01 | -3.53 | Upgrade
|
| EBT Excluding Unusual Items | 445.37 | 438.85 | 283.95 | 278.91 | 159.74 | 192.42 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -48.3 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 4.49 | 19 | -3.04 | -5.35 | -4.17 | 1.34 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.16 | 0.18 | 0.35 | 1.12 | 0.12 | 0.15 | Upgrade
|
| Asset Writedown | -79.11 | -83.58 | -27.53 | -84.97 | -9.75 | -22.97 | Upgrade
|
| Other Unusual Items | - | - | 38.37 | 29.26 | 28.02 | 30.66 | Upgrade
|
| Pretax Income | 370.9 | 374.46 | 292.11 | 218.98 | 125.65 | 201.59 | Upgrade
|
| Income Tax Expense | 70.1 | 74.56 | 68.19 | 39.07 | 21.04 | 17.83 | Upgrade
|
| Earnings From Continuing Operations | 300.8 | 299.9 | 223.92 | 179.91 | 104.6 | 183.76 | Upgrade
|
| Minority Interest in Earnings | 18.6 | 20.11 | 18.77 | 19.67 | 0.05 | 3.33 | Upgrade
|
| Net Income | 319.41 | 320.01 | 242.69 | 199.59 | 104.66 | 187.09 | Upgrade
|
| Net Income to Common | 319.41 | 320.01 | 242.69 | 199.59 | 104.66 | 187.09 | Upgrade
|
| Net Income Growth | 34.38% | 31.86% | 21.60% | 90.71% | -44.06% | 74.25% | Upgrade
|
| Shares Outstanding (Basic) | 696 | 699 | 723 | 763 | 770 | 770 | Upgrade
|
| Shares Outstanding (Diluted) | 696 | 699 | 723 | 763 | 770 | 770 | Upgrade
|
| Shares Change (YoY) | -2.72% | -3.29% | -5.25% | -0.89% | 0.02% | -0.04% | Upgrade
|
| EPS (Basic) | 0.46 | 0.46 | 0.34 | 0.26 | 0.14 | 0.24 | Upgrade
|
| EPS (Diluted) | 0.46 | 0.46 | 0.34 | 0.26 | 0.14 | 0.24 | Upgrade
|
| EPS Growth | 38.14% | 36.35% | 28.34% | 92.42% | -44.07% | 74.32% | Upgrade
|
| Free Cash Flow | 573.06 | 524.91 | 437.03 | 397.7 | 398.23 | 342.45 | Upgrade
|
| Free Cash Flow Per Share | 0.82 | 0.75 | 0.60 | 0.52 | 0.52 | 0.45 | Upgrade
|
| Dividend Per Share | - | - | 0.300 | 0.150 | 0.050 | 0.080 | Upgrade
|
| Dividend Growth | - | - | 100.00% | 200.00% | -37.50% | 60.00% | Upgrade
|
| Gross Margin | 52.58% | 52.51% | 50.73% | 57.19% | 55.27% | 60.39% | Upgrade
|
| Operating Margin | 16.03% | 15.61% | 10.31% | 10.02% | 6.55% | 7.12% | Upgrade
|
| Profit Margin | 14.54% | 14.29% | 9.04% | 6.86% | 3.85% | 6.77% | Upgrade
|
| Free Cash Flow Margin | 26.08% | 23.43% | 16.27% | 13.67% | 14.65% | 12.39% | Upgrade
|
| EBITDA | 485.88 | 483.77 | 412.82 | 447.11 | 338.04 | 363.93 | Upgrade
|
| EBITDA Margin | 22.11% | 21.60% | 15.37% | 15.37% | 12.44% | 13.17% | Upgrade
|
| D&A For EBITDA | 133.58 | 134.06 | 135.98 | 155.61 | 159.97 | 167.27 | Upgrade
|
| EBIT | 352.3 | 349.71 | 276.84 | 291.5 | 178.07 | 196.65 | Upgrade
|
| EBIT Margin | 16.03% | 15.61% | 10.31% | 10.02% | 6.55% | 7.12% | Upgrade
|
| Effective Tax Rate | 18.90% | 19.91% | 23.34% | 17.84% | 16.75% | 8.85% | Upgrade
|
| Revenue as Reported | - | - | 2,686 | 2,910 | 2,718 | 2,764 | Upgrade
|
| Advertising Expenses | - | - | 131.24 | 119.31 | 105.5 | 100.49 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.